Further Extension to ECA Foundation Executive Advisory Board

The ECA Foundation, which was established in 1999, is headed by an Executive Team comprised of four members. This Executive Board is further supported by an Extended Board. In this Board the various ECA Interest and Working Groups are represented by their Chairpersons. Now the ECA Foundation announced that the organisation’s Executive Advisory Board will be extended by Dr Andreas König who has accepted the Board’s invitation to join the ECA’s Executive Team with immediate effect.

After studying pharmacy at the Philipps University in Marburg and completing his doctorate at the Julius-Maximilians University in Würzburg, Dr König initially worked at Fresenius Kabi as Deputy Director QC & QA and as Director QC & QA and Qualified Person. In the following years, he was Head of Quality Operations and Global Quality Director at Intervet International before moving to Schering-Plough in 2008 as Vice President Global Quality Operations Animal Health. From 2010-2014, as Vice President Manufacturing & Quality, he managed the entire Manufacturing Network of Aenova with 12 manufacturing sites with more than 2000 FTE and then, until 2016, as Senior Vice President Corporate Quality & HSE, the Quality and HSE of Aenova-Group with 18 manufacturing sites and more than 700 FTE in Quality. Subsequently, he was Managing Director for Fidelio Healthcare, a young dynamic CDMO for the Pharmaceutical and HealthCare Industry and Head of Technical Operations at MiP Pharma Group. Since 2010 he is also Managing Director and owner of his consulting company, providing services to the pharmaceutical industry. With his wealth of experience and expertise in areas such as quality assurance, manufacturing, regulatory affairs, technology transfer, validation, and radiopharmaceuticals "we will be really pleased to have him on board, he will be a good ally and expert in the team" said Dr Afshin Hosseiny, Chairman of the ECA Foundation Executive Board.

Find out more about the ECA Foundation Team.

Back to news overview

x